P. vivax requires radical cure for control of blood and liver stages. Primaquine is the only widely available drug to kill liver stage vivax malaria, however, it can cause severe haemolysis in individuals with glucose-6-phosphate dehydrogenase deficiency. Many countries and clinicians are reluctant to prescribe primaquine for this reason. We have used individual patient data meta-analyses undertaken through collaboration with the WorldWide Antimalarial Resistance Netowrk (WWARN) to improve our understanding of the risks and benefits of primaquine radical cure and inform policymakers.
- The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis
- The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis
- The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis